Rare Bleeding Disorders: Disability & Death Risk | Samaan Lateef Report

A critical shortage of blood clotting factors is threatening the lives of hemophilia patients in Afghanistan, leaving hundreds at risk of debilitating complications and even death. The crisis, reported as of February 15, 2026, highlights the fragility of healthcare systems in conflict zones and the devastating consequences of disrupted medical supply chains.

The Hemophilia Crisis in Afghanistan

Hemophilia is a rare genetic bleeding disorder where the blood doesn’t clot normally due to a lack of, or deficiency in, blood clotting factors. Individuals with hemophilia require regular infusions of these factors – specifically factor VIII or factor IX – to prevent and control bleeding episodes. Without access to these essential treatments, even minor injuries can lead to prolonged and life-threatening internal bleeding.

The current situation in Afghanistan is particularly dire. According to reports, a severe lack of factor IX and factor VIII is impacting hundreds of patients. This shortage isn’t simply a matter of inconvenience; it directly translates to a heightened risk of uncontrolled internal bleeding, permanent disability, and potentially fatal outcomes. The Lancet reports that the situation is a critical shortage.

Bleeding and its Consequences

Bleeding complications, as highlighted in research on traumatic hemorrhage, can have far-reaching consequences beyond immediate mortality. A study published in the Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine in May 2023, emphasizes the importance of early intervention in trauma-related bleeding. While focused on traumatic injuries, the underlying principles apply to bleeding disorders like hemophilia – prompt management is crucial to minimize harm.

Recent research examining bleeding during Venoarterial ECMO (VA ECMO) support demonstrates that bleeding events are associated with increased risk of both new disability and death. A study published in 2024 (data collected February 2019 – June 2023) found that bleeding complications increased the rate of death and disability at six months, with the increase primarily driven by new disability rather than mortality. The study, involving 704 participants, showed a risk difference of 8.95% for the composite outcome of death or new disability in those experiencing bleeding complications.

The definition of “new disability” in the study was defined as an increase of at least 10% in the World Health Organization disability assessment schedule score, underscoring the significant functional impact of bleeding events. The research also noted that patients experiencing bleeding were more likely to be receiving VA ECMO for peri-operative support.

Understanding Hematological Disorders and Disability

The Social Security Administration (SSA) provides a framework for understanding hematological disorders and their potential impact on disability. Their “Blue Book” outlines categories of impairments, including hemolytic anemias (like sickle cell disease and thalassemia), disorders of thrombosis and hemostasis (affecting blood clotting), and disorders of bone marrow failure. Repeated complications arising from these hematological disorders can also be grounds for disability consideration.

The SSA’s classification highlights the long-term and potentially debilitating nature of these conditions. The increased risk of disability observed in the VA ECMO study reinforces this point, demonstrating that bleeding complications can lead to lasting functional impairments.

Bleeding Disorders: Beyond Hemophilia

While the current crisis in Afghanistan specifically concerns hemophilia, it’s important to recognize that a range of bleeding disorders exist. The National Bleeding Disorders Foundation provides information on hemophilia and other rare bleeding disorders. These conditions can manifest in various ways and require specialized care.

The potential for long-term complications associated with bleeding disorders extends beyond immediate mortality and disability. Research suggests a possible link to cardiovascular events, malignancies, and neurological issues, necessitating ongoing monitoring and comprehensive management.

The Role of TXA

Research into managing traumatic hemorrhage suggests a potential role for tranexamic acid (TXA). The CRASH-2 trial indicates that early administration of TXA (within three hours of injury) can reduce the risk of death in bleeding trauma patients. While this research focuses on trauma, it highlights the importance of timely intervention in controlling bleeding, a principle applicable to managing bleeding episodes in individuals with hemophilia and other bleeding disorders.

Looking Ahead

The situation in Afghanistan underscores the critical need for sustained access to essential medications and healthcare resources, particularly in regions affected by conflict and instability. Addressing this crisis requires a coordinated international effort to ensure that individuals with hemophilia and other bleeding disorders receive the life-saving treatments they desperately need. Further prospective studies are needed to identify modifiable risk factors for bleeding complications and to improve patient outcomes.